HealthQuill Switzerland
https://www.novartis.com/research-and-development/research-disease-areas/cardiovascular-and-metabolic-disease-research-novartis
Drugs Health Pharma

Novartis signs $5.2 billion pact with China’s Argo Biopharmaceutical

HQ Team September 4, 2025: China’s Argo Biopharmaceutical Co., Ltd., and Switzerland’s Novartis AG have inked a $5.2 billion pact to develop new.

Read More
Novartis AG’s treatment for malaria in infants and newborns weighing between two and five kilograms has been approved in Switzerland, and eight African nations are set to follow.
Drugs Health Pharma

Novartis malaria drug for infants gets Swiss nod, 8 African nations in line

HQ Team July 8, 2025: Novartis AG’s treatment for malaria in infants and newborns weighing between two and five kilograms has been approved.

Read More
Pfizer Inc. will pay Basilea Pharmaceutica Ltd. $ 2.5 million as the Swiss biopharmaceutical company exceeded the sales threshold of its antifungal therapy in the Asia Pacific region, triggering a milestone payment.
Drugs Health Pharma

Sales surge triggers Pfizer’s $2.5 million milestone payment to Basilea

HQ Team June 5, 2025: Pfizer Inc. will pay Basilea Pharmaceutica Ltd. $ 2.5 million as the Swiss biopharmaceutical company exceeded the sales.

Read More
Swiss-American Alcon Inc.’s acoltremon ophthalmic solution, Tryptyr, has received a green signal from the US Food and Drug Administration to treat dry eye disease.
Drugs Health Medical

Alcon’s medicine for dry eye disease gets approval from US regulator

HQ Team May 29, 2025: Swiss-American Alcon Inc.’s acoltremon ophthalmic solution, Tryptyr, has received a green signal from the US Food and Drug.

Read More
Long-standing allies and new contributors have stepped up funding to the cash-strapped World Health Organization with a total of $170 million.
Drugs Health Pharma

Governments, philanthropic partners pledge $170 million to WHO

HQ Team May 21, 2025: Long-standing allies and new contributors have stepped up funding to the cash-strapped World Health Organization with a total.

Read More
Switzerland’s pharmaceutical company, Novartis AG,  will acquire Regulus Therapeutics for about $1.7 billion to get access to a drug to treat a genetic kidney disease called autosomal dominant polycystic kidney disease.
Drugs Health Pharma

Novartis buys Regulus for $1.7b to grab genetic kidney disease drug

HQ Team April 30, 2025: Switzerland’s pharmaceutical company, Novartis AG,  will acquire Regulus Therapeutics for about $1.7 billion to get access to a.

Read More
Swiss healthcare multinational F. Hoffmann-La Roche AG will invest $50 billion in the US over the next five years to expand its research and manufacturing facilities.
Drugs Medical Pharma

Roche to invest $50 billion in US over next five years to expand capacity

HQ Team April 22, 2025: Swiss healthcare multinational F. Hoffmann-La Roche AG will invest $50 billion in the US over the next five.

Read More
Anglo-Swedish AstraZeneca Plc., and Japan’s Daiichi Sankyo’s therapy to treat a certain form of breast cancer has been approved by the US drug regulator in the adult population. 
Drugs Health Pharma

AstraZeneca-Daiichi’s breast cancer drug gets broader US nod

Anglo-Swedish AstraZeneca Plc., and Japan’s Daiichi Sankyo’s therapy to treat a certain form of breast cancer has been approved by the US drug.

Read More
Switzerland’s F. Hoffmann-La Roche AG will buy US-based biopharmaceutical company Poseida Therapeutics for $1.5 billion, according to a statement from the Basel-headquartered company.
Drugs Health Pharma

Roche to acquire US-based Poseida Therapeutics for $1.5 billion

Switzerland’s F. Hoffmann-La Roche AG will buy US-based biopharmaceutical company Poseida Therapeutics for $1.5 billion, according to a statement from the Basel-headquartered company.

Read More
British-Swedish AstraZeneca’s drug for treatment of a form of blood cancer has been granted a Priority Review in the US by the drug regulator.
Drugs Health Pharma

AstraZeneca’s experimental blood cancer drug gets US priority review

British-Swedish AstraZeneca’s drug for treatment of a form of blood cancer has been granted a Priority Review in the US by the drug.

Read More